To Örebro University

oru.seÖrebro University Publications
Change search
Refine search result
1 - 14 of 14
CiteExportLink to result list
Permanent link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Rows per page
  • 5
  • 10
  • 20
  • 50
  • 100
  • 250
Sort
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
Select
The maximal number of hits you can export is 250. When you want to export more records please use the Create feeds function.
  • 1.
    Hosseini-Mellner, Servah
    et al.
    Örebro University, School of Medical Sciences. Department of Surgery, Södersjukhuset, Stockholm, Sweden.
    Wickberg, Åsa
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Surgery.
    Karakatsanis, Andreas
    Department of Surgical Sciences, Uppsala University Hospital, Uppsala University, Uppsala, Sweden; Department of Surgery, Uppsala University Hospital, Uppsala, Sweden.
    Valachis, Antonis
    Department of Oncology.
    Impact of neoadjuvant compared to adjuvant chemotherapy on prognosis in patients with hormone-receptor positive / HER2-negative breast cancer: A propensity score matching population-based study2024In: Breast, ISSN 0960-9776, E-ISSN 1532-3080, Vol. 76, article id 103741Article in journal (Refereed)
    Abstract [en]

    BACKGROUND: The aim of this population-based cohort study was to investigate the impact of neoadjuvant chemotherapy (NACT) compared to adjuvant chemotherapy in prognosis among patients with HR+/HER2 negative breast cancer.

    METHOD: This population-based study utilized data from the research database BCBaSe 3.0, based on the Swedish National Quality breast cancer register, including all patients with breast cancer diagnosis in Sweden between 2008 and 2019. Propensity score matching approach was applied. The outcomes of interest consisted of distant-disease free (DDFS), breast-cancer specific (BCSS), and overall survival (OS).

    RESULTS: In total, 14 459 patients were included in the study cohort of whom 2086 received NACT. After 1:1 propensity score matching (PSM), 1539 patients in each study group were available for analyses. No statistically significant difference in survival outcomes were observed between patients treated with NACT compared to those treated with adjuvant chemotherapy (Hazard Ratio (HR) for DDFS: 1.20; 95 % CI: 0.80-1.79; HR for BCSS: 1.16; 95 % CI: 0.54-2.49; HR for OS: 1.14; 95 % CI: 0.64-2.05).

    CONCLUSION: In this population-based cohort study of patients with HR+/HER2-breast cancer, the use of NACT seems to be comparable to adjuvant chemotherapy in terms of prognosis, although non-inferiority cannot be proven by this study design. Until further evidence suggesting a survival benefit in favor of either treatment is available, NACT can be pursued when surgical-de-escalation is intended.

  • 2.
    Obondo, C.
    et al.
    Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
    Karakatsanis, A.
    Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
    Eriksson, S.
    Department of Surgery, Central Hospital, Västerås, Sweden.
    Hersi, A. F.
    Department of Surgery, Central Hospital, Västerås, Sweden.
    Pistiolis, L.
    Department of Surgery, Sahlgrenska University Hospital, Göteborg, Sweden.
    Shahin, A.
    Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
    Nilsson, F.
    Department of Surgery and Perioperative Sciences, Umeå University, Umeå, Sweden.
    Mohammed, I.
    Department of Surgery, Kalmar Hospital, Kalmar, Sweden.
    Wickberg, Åsa
    Örebro University, School of Medical Sciences. Department of Surgery, Örebro University Hospital, Örebro, Sweden.
    Wärnberg, F.
    Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
    SentiDose - A dose optimizing study with SiennaXP, a superparamagnetic iron oxide for sentinel node detection2018In: European Journal of Cancer, ISSN 0959-8049, E-ISSN 1879-0852, Vol. 92, no Suppl. 3, p. S79-S79Article in journal (Other academic)
  • 3.
    Ohlsson-Nevo, Emma
    et al.
    Örebro University, School of Health Sciences. Örebro University Hospital. University Health Care Research Center.
    Arvidsson Lindvall, Mialinn
    Örebro University, School of Health Sciences. Örebro University Hospital. University Health Care Research Center.
    Hellerstedt Börjeson, Susanne
    Department of Public Health and Caring Sciences, Center for Clinical Research, Uppsala University, Uppsala, Sweden.
    Hagberg, Lars
    Örebro University, School of Health Sciences. Örebro University Hospital. University Health Care Research Center.
    Hultgren Hörnquist, Elisabeth
    Örebro University, School of Medical Sciences.
    Valachis, Antonios
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Oncology.
    Wickberg, Åsa
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Surgery.
    Duberg, Anna
    Örebro University, School of Health Sciences. Örebro University Hospital. University Health Care Research Center.
    Digitally distributed Yoga Intervention in Breast Cancer Rehabilitation (DigiYoga CaRe): protocol for a randomised controlled trial2022In: BMJ Open, E-ISSN 2044-6055, Vol. 12, no 11, article id e065939Article in journal (Refereed)
    Abstract [en]

    INTRODUCTION: Breast cancer is the most prevalent cancer among women. The treatment is extensive; in addition to surgery, various combinations of radiation therapy, chemotherapy and antibody and endocrine treatment can be applied. Cancer-related fatigue (CRF) is high in patients with breast cancer, peaking during chemotherapy, but may persist for several years. Physical activity has proven to be effective in reducing CRF in breast cancer rehabilitation, but many patients tend to be less active after the diagnosis. Yoga has a previously demonstrated effect on energy levels and digitally distributed yoga intervention can potentially increase accessibility in pandemic times and facilitate participation for patients susceptible to infection and those living far from organised rehabilitation opportunities. The purpose of this study, Digital Yoga Intervention in Cancer Rehabilitation (DigiYoga CaRe) is to investigate whether a 12-week digitally distributed yoga intervention can reduce CRF and stress, improve health-related quality of life (HRQL) and affect pro-inflammatory and metabolic markers in patients with breast cancer.

    METHODS AND ANALYSIS: This multicentre study will adopt a randomised controlled design including 240 persons after their breast cancer surgery. They will be randomised to a 12-week digitally distributed yoga intervention or to a control group. The intervention group practice yoga two times a week, one yoga class live-streamed to the patient's computer or mobile device and one prerecorded video class for self-training. The controls receive standardised care, gift cards for flowers and access to yoga video links after the data collection has ended. The primary analysis will be performed following the principle of intention to treat. Data will be collected by questionnaires, blood samples, accelerometers and interviews.

    ETHICS AND DISSEMINATION: The DigiYoga CaRe study was approved by the Regional Ethical Review Board in Lund. The final results of this study will be disseminated to conference, patient and public involvements and peer-reviewed publications.

    TRIAL REGISTRATION NUMBER: NCT04812652.

  • 4.
    Ohlsson-Nevo, Emma
    et al.
    Örebro University, School of Health Sciences. Örebro University Hospital.
    Arvidsson Lindvall, Mialinn
    Örebro University, School of Health Sciences. Örebro University Hospital.
    Hellerstedt Börjesson, Susanne
    Uppsala University, Uppsala, Sweden.
    Hagberg, Lars
    Örebro University, School of Health Sciences. Örebro University Hospital.
    Hultgren Hörnquist, Elisabeth
    Örebro University, School of Medical Sciences.
    Valachis, Antonis
    Örebro University, School of Medical Sciences.
    Wickberg, Åsa
    Örebro University, School of Medical Sciences. Örebro University Hospital.
    Duberg, Anna
    Örebro University, School of Health Sciences. Örebro University Hospital.
    A Digitally Distributed Yoga Intervention in Breast Cancer Rehabilitation (DigiYogaCaRe): Protocol for a Randomized Controlled Trial2023Conference paper (Other academic)
  • 5.
    Olander, Susanne
    et al.
    Department of Surgery, Sunderby Hospital, Luleå, Sweden.
    Wennstig, Anna-Karin
    Department of Surgery and Perioperative sciences/Surgery, Umeå University, Umeå, Sweden; Department of Oncology, Sundsvall Hospital, Sundsvall, Sweden.
    Garmo, Hans
    Regional Cancer Center, Uppsala University, Uppsala, Sweden.
    Holmberg, Lars
    Regional Cancer Center, Uppsala University, Uppsala, Sweden; Translational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King’s College London, London, UK.
    Nilsson, Greger
    Department of Immunology, Genetics and Pathology, Section of Experimental and Clinical Oncology, Uppsala University, University Hospital, Uppsala, Sweden; Department of Oncology, Gävle Hospital, Gävle, Sweden; Department of Oncology, Visby Hospital, Visby, Sweden.
    Blomqvist, Carl
    Department of Oncology, Helsinki University Hospital, Helsinki, Finland; Department of Oncology, Örebro University Hospital, Örebro, Sweden.
    Karlsson, Fredrik
    Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden; Department of Breast, Endocrine Tumours and Sarcoma, Karolinska University Hospital, Stockholm, Sweden.
    Wickberg, Åsa
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Surgery.
    Wärnberg, Fredrik
    Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
    Sund, Malin
    Department of Surgery and Perioperative sciences/Surgery, Umeå University, Umeå, Sweden; Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Sweden.
    Wadsten, Charlotta
    Department of Surgery and Perioperative sciences/Surgery, Umeå University, Umeå, Sweden; Department of Surgery, Sundsvall Hospital, Sundsvall, Sweden.
    Angiosarcoma in the breast: a population-based cohort from Sweden2023In: British Journal of Surgery, ISSN 0007-1323, E-ISSN 1365-2168, Vol. 110, no 12, p. 1850-1856Article in journal (Refereed)
    Abstract [en]

    Background: Breast angiosarcoma is a rare disease mostly observed in breast cancer (BC) patients who have previously received radiotherapy (RT). Little is known about angiosarcoma aetiology, management, and outcome. The study aim was to estimate risk and to characterize breast angiosarcoma in a Swedish population-based cohort.

    Methods: The Swedish Cancer Registry was searched for breast angiosarcoma between 1992 and 2018 in three Swedish healthcare regions (population 5.5 million). Information on previous BC, RT, management, and outcome were retrieved from medical records.

    Results: Overall, 49 angiosarcomas located in the breast, chest wall, or axilla were identified, 8 primary and 41 secondary to BC treatment. Median age was 51 and 73 years, respectively. The minimum latency period of secondary angiosarcoma after a BC diagnosis was 4 years (range 4-21 years). The cumulative incidence of angiosarcoma after breast RT increased continuously, reaching 1.4 & PTSTHOUSND; after 20 years. Among 44 women with angiosarcoma treated by surgery, 29 developed subsequent local recurrence. Median recurrence-free survival was 3.4 and 1.8 years for primary and secondary angiosarcoma, respectively. The 5-year overall survival probability for the whole cohort was 50 per cent (95 per cent c.i., 21 per cent-100 per cent) for primary breast angiosarcoma and 35 per cent (95 per cent c.i., 23 per cent-54 per cent) for secondary angiosarcoma.

    Conclusion: Breast angiosarcoma is a rare disease strongly associated with a history of previous BC RT. Overall survival is poor with high rates of local recurrences and distant metastasis.

  • 6.
    Villman, Kenneth
    et al.
    Department of Oncology, Örebro University Hospital, Örebro, Sweden.
    Wickberg, Åsa
    Örebro University, School of Medical Sciences. Department of Surgery, Faculty of Health and Medical Sciences, Örebro University, Örebro, Sweden.
    Killander, Fredrika
    Skåne University Hospital and Lund University, Lund, Sweden.
    Lindman, Henrik
    Akademic Hospital, Uppsala University, Uppsala, Sweden.
    Bjöhle, Judith
    Karolinska Institutet and University Hospital, Stockholm, Sweden.
    Edlund, P.
    Tennvall-Nittby, L.
    Carlberg, Michael
    Department of Oncology, Örebro University Hospital, Örebro, Sweden.
    Bachmeier, K.
    Blomqvist, Carl
    Department of Oncology, Helsinki University, Helsinki, Finland.
    Ahlgren, Johan
    Department of Oncology, Örebro University Hospital, Örebro, Sweden.
    Liljegren, Göran
    Department of Surgery, Örebro University Hospital, Örebro, Sweden.
    Omitting radiotherapy in women >= 65 years with low-risk early breast cancer after breast-conserving surgery and adjuvant endocrine therapy is safe2017In: Cancer Research, ISSN 0008-5472, E-ISSN 1538-7445, Vol. 77, no 4 Sup., article id P1-10-05Article in journal (Other academic)
  • 7.
    Wickberg, Åsa
    Örebro University, School of Medical Sciences.
    Adjuvant treatments to prevent local reurrence after breast-conserving surgery for early breast cancer: radiation, endocrine- or brachytherapy2018Doctoral thesis, comprehensive summary (Other academic)
    Abstract [en]

    Radiotherapy after breast-conserving surgery due to breast cancer is an established treatment, known to reduce the incidence of recurrence and even death from the disease. However some women are over-treated with sometimes serious adverse effects. De-escalating the treatment and find alternative adjuvant methods are becoming an important issue. In study I, we present the outcomes from a long-term follow-up trial randomising 381 women with breast cancer to surgery alone or to surgery with the addition of radiotherapy. The incidence of any first breast cancer event was significantly higher without radiotherapy but the protecting effect lasted for only the first five years. In study II, we collected the tissue samples from the tumours in study I to construct tissue micro-arrays. Immuno-histochemical analyses were performed and the tumours were classified into the intrinsic subtypes. The luminal B/HER2 negative subtype was found to be prognostic for ipsilateral breast cancer recurrence (IBTR). The intrinsic subtypes did not interact with radiotherapy. Study III was a multicentre prospective cohort study where the 601 study participants with early breast cancer were treated with surgery and endocrine therapy alone without postoperative radiotherapy. The cumulative incidence of IBTR after five years was low -1.2% and only one woman died of breast cancer. In study IV we evaluated the feasibility and treatment complications when introducing a new method for intraoperative brachytherapy (IOBT) using HDR equipment. We designed a pilot study including fifty women where half of them were treated during primary surgery and the others during a second procedure. The treatment was well tolerated and no logistic problems were reported. No acute adverse effects from IOBT were seen.

    List of papers
    1. Sector Resection With or Without Postoperative Radiotherapy for Stage I Breast Cancer: 20-Year Results of a Randomized Trial
    Open this publication in new window or tab >>Sector Resection With or Without Postoperative Radiotherapy for Stage I Breast Cancer: 20-Year Results of a Randomized Trial
    Show others...
    2014 (English)In: Journal of Clinical Oncology, ISSN 0732-183X, E-ISSN 1527-7755, Vol. 32, no 8, p. 791-797Article in journal (Refereed) Published
    Abstract [en]

    Purpose: To investigate how radiotherapy (XRT) adds to tumor control using a standardized surgical technique with meticulous control of surgical margins in a randomized trial with 20 years of follow-up.

    Patients and Methods: Three hundred eighty-one women with pT1N0 breast cancer were randomly assigned to sector resection with (XRT group) or without (non-XRT group) postoperative radiotherapy to the breast. With follow-up through 2010, we estimated cumulative proportion of recurrence, breast cancer death, and all-cause mortality.

    Results: The cumulative probability of a first breast cancer event of any type after 20 years was 30.9% in the XRT group and 45.1% in the non-XRT group (hazard ratio [HR], 0.58; 95% CI, 0.41 to 0.82). The benefit of radiotherapy was achieved within the first 5 years. After 20 years, 50.4% of the women in the XRT group died compared with 54.0% in the non-XRT group (HR, 0.92; 95% CI, 0.71 to 1.19). The cumulative probability of contralateral cancer or death as a result of cancer other than breast cancer was 27.1% in the XRT group and 24.9% in the non-XRT group (HR, 1.17; 95% CI, 0.77 to 1.77). In an anticipated low-risk group, the cumulative incidence of first breast cancer of any type was 24.8% in the XRT group and 36.1% in the non-XRT group (HR, 0.61; 95% CI, 0.35 to 1.07).

    Conclusion: Radiotherapy protects against recurrences during the first 5 years of follow-up, indicating that XRT mainly eradicates undetected cancer foci present at primary treatment. The similar rate of recurrences beyond 5 years in the two groups indicates that late recurrences are new tumors. There are subgroups with clinically relevant differences in risk.

    Place, publisher, year, edition, pages
    American Society of Clinical Oncology, 2014
    National Category
    Cancer and Oncology
    Identifiers
    urn:nbn:se:oru:diva-56811 (URN)10.1200/JCO.2013.50.6600 (DOI)000332483400016 ()24493730 (PubMedID)2-s2.0-84899626690 (Scopus ID)
    Available from: 2017-03-24 Created: 2017-03-24 Last updated: 2020-12-01Bibliographically approved
    2. Influence of the subtype on local recurrence risk with or without radiotherapy in a randomized trial
    Open this publication in new window or tab >>Influence of the subtype on local recurrence risk with or without radiotherapy in a randomized trial
    Show others...
    (English)Manuscript (preprint) (Other academic)
    National Category
    Surgery
    Identifiers
    urn:nbn:se:oru:diva-66947 (URN)
    Available from: 2018-05-15 Created: 2018-05-15 Last updated: 2018-09-18Bibliographically approved
    3. Omitting radiotherapy in women ≥ 65 years with low-risk early breast cancer after breast-conserving surgery and adjuvant endocrine therapy is safe
    Open this publication in new window or tab >>Omitting radiotherapy in women ≥ 65 years with low-risk early breast cancer after breast-conserving surgery and adjuvant endocrine therapy is safe
    Show others...
    (English)Manuscript (preprint) (Other academic)
    National Category
    Surgery
    Identifiers
    urn:nbn:se:oru:diva-66948 (URN)
    Available from: 2018-05-15 Created: 2018-05-15 Last updated: 2018-05-18Bibliographically approved
    4. Intraoperative high dose rate brachytherapy during breast-conserving surgery: a prospective pilot study
    Open this publication in new window or tab >>Intraoperative high dose rate brachytherapy during breast-conserving surgery: a prospective pilot study
    Show others...
    (English)Manuscript (preprint) (Other academic)
    National Category
    Surgery
    Identifiers
    urn:nbn:se:oru:diva-66949 (URN)
    Available from: 2018-05-15 Created: 2018-05-15 Last updated: 2020-12-01Bibliographically approved
    Download (pdf)
    Spikblad
    Download (pdf)
    Cover
  • 8.
    Wickberg, Åsa
    et al.
    Örebro University, School of Medical Sciences.
    Holmberg, Lars
    Medical School, King's College, London, United Kingdom; Uppsala University, Uppsala, Sweden.
    Adami, Hans-Olov
    Harvard School of Public Health, Boston MA, United States.
    Magnuson, Anders
    Örebro University Hospital, Örebro, Sweden.
    Villman, Kenneth
    Örebro University Hospital.
    Liljegren, Göran
    Örebro University Hospital, Örebro, Sweden.
    Reply to a. Levy et Al.2014In: Journal of Clinical Oncology, ISSN 0732-183X, E-ISSN 1527-7755, Vol. 32, no 29, p. 3340-3341Article in journal (Refereed)
  • 9.
    Wickberg, Åsa
    et al.
    Örebro University, School of Medical Sciences. Örebro University Hospital, Örebro, Sweden; Uppsala University, Uppsala, Sweden.
    Holmberg, Lars
    Uppsala University, Uppsala, Sweden; Kings Coll, London, England.
    Adami, Hans-Olov
    Karolinska Institutet, Stockholm, Sweden; Harvard School of Public Health, Boston MA, USA.
    Magnuson, Anders
    Örebro University Hospital, Örebro, Sweden.
    Villman, Kenneth
    Örebro University Hospital.
    Liljegren, Göran
    Örebro University Hospital.
    Sector Resection With or Without Postoperative Radiotherapy for Stage I Breast Cancer: 20-Year Results of a Randomized Trial2014In: Journal of Clinical Oncology, ISSN 0732-183X, E-ISSN 1527-7755, Vol. 32, no 8, p. 791-797Article in journal (Refereed)
    Abstract [en]

    Purpose: To investigate how radiotherapy (XRT) adds to tumor control using a standardized surgical technique with meticulous control of surgical margins in a randomized trial with 20 years of follow-up.

    Patients and Methods: Three hundred eighty-one women with pT1N0 breast cancer were randomly assigned to sector resection with (XRT group) or without (non-XRT group) postoperative radiotherapy to the breast. With follow-up through 2010, we estimated cumulative proportion of recurrence, breast cancer death, and all-cause mortality.

    Results: The cumulative probability of a first breast cancer event of any type after 20 years was 30.9% in the XRT group and 45.1% in the non-XRT group (hazard ratio [HR], 0.58; 95% CI, 0.41 to 0.82). The benefit of radiotherapy was achieved within the first 5 years. After 20 years, 50.4% of the women in the XRT group died compared with 54.0% in the non-XRT group (HR, 0.92; 95% CI, 0.71 to 1.19). The cumulative probability of contralateral cancer or death as a result of cancer other than breast cancer was 27.1% in the XRT group and 24.9% in the non-XRT group (HR, 1.17; 95% CI, 0.77 to 1.77). In an anticipated low-risk group, the cumulative incidence of first breast cancer of any type was 24.8% in the XRT group and 36.1% in the non-XRT group (HR, 0.61; 95% CI, 0.35 to 1.07).

    Conclusion: Radiotherapy protects against recurrences during the first 5 years of follow-up, indicating that XRT mainly eradicates undetected cancer foci present at primary treatment. The similar rate of recurrences beyond 5 years in the two groups indicates that late recurrences are new tumors. There are subgroups with clinically relevant differences in risk.

  • 10.
    Wickberg, Åsa
    et al.
    Örebro University, School of Medical Sciences.
    Liljegren, Göran
    Department of surgery, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    Ahlgren, Johan
    Department of oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    Karlsson, Leif
    Department of oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    With, Anders
    Department of oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    Johansson, Bengt
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department of oncology.
    Intraoperative high dose rate brachytherapy during breast-conserving surgery: a prospective pilot studyManuscript (preprint) (Other academic)
  • 11.
    Wickberg, Åsa
    et al.
    Örebro University, School of Medical Sciences. Department of surgery.
    Liljegren, Göran
    Department of surgery, Faculty of Medicine and Health,Örebro SE-701 82 Örebro, Sweden.
    Killander, Fredrika
    Skåne University Hospital and Lund University, Lund, Sweden.
    Lindman, Henrik
    Akademic Hospital, Uppsala University, Uppsala, Sweden .
    Bjöhle, Judith
    Karolinska Institutet and University Hospital, Stockholm, Sweden.
    Carlberg, Michael
    Department of oncology, Faculty of Medicine and Health, Örebro, Örebro, Sweden.
    Blomqvist, Carl
    Department of Oncology Helsinki University, Finland.
    Ahlgren, Johan
    Department of oncology, Faculty of Medicine and Health, Örebro, Sweden.
    Villman, Kenneth
    Department of oncology, Faculty of Medicine and Health, Örebro, Sweden.
    Omitting radiotherapy in women ≥ 65 years with low-risk early breast cancer after breast-conserving surgery and adjuvant endocrine therapy is safeManuscript (preprint) (Other academic)
  • 12.
    Wickberg, Åsa
    et al.
    Örebro University, School of Medical Sciences. Department of Surgery, Faculty of Health and Medical Sciences, Örebro University, Örebro, Sweden.
    Liljegren, Göran
    Department of Surgery, Örebro University Hospital, Örebro, Sweden.
    Killander, Fredrika
    Skåne University Hospital and Lund University, Lund, Sweden.
    Lindman, Henrik
    Akademic Hospital, Uppsala University, Uppsala, Sweden.
    Bjöhle, Judith
    Karolinska Institutet and University Hospital, Stockholm, Sweden.
    Carlberg, Michael
    Department of Oncology, Örebro University Hospital, Örebro, Sweden.
    Blomqvist, Carl
    Department of Oncology, Helsinki University, Helsinki, Finland.
    Ahlgren, Johan
    Department of Oncology, Örebro University Hospital, Örebro, Sweden.
    Villman, Kenneth
    Department of Oncology, Örebro University Hospital, Örebro, Sweden.
    Omitting radiotherapy in women >= 65 years with low-risk early breast cancer after breast-conserving surgery and adjuvant endocrine therapy is safe2018In: European Journal of Surgical Oncology, ISSN 0748-7983, E-ISSN 1532-2157, Vol. 44, no 7, p. 951-956Article in journal (Refereed)
    Abstract [en]

    Purpose: The aim of this study was to verify if radiotherapy (RT) safely can be omitted in older women treated for estrogen-receptor positive early breast cancer with breast-conserving surgery (BCS) and endocrine therapy (ET).

    Patients and Methods: Eligibility criteria were: consecutive patients with age >= 65 years, BCS + sentinel node biopsy, clear margins, unifocal T1N0M0 breast cancer tumor, Elston-Ellis histological grade 1 or 2 and estrogen receptor-positive tumor. After informed consent, adjuvant ET for 5 years was prescribed. Primary endpoint was ipsilateral breast tumor recurrence (IBTR). Secondary endpoints were contralateral breast cancer and overall survival.

    Results: Between 2006 and 2012, 603 women were included from 14 Swedish centers. Median age was 71.1 years (range 65-90). After a median follow-up of 68 months 16 IBTR (cumulative incidence at five-year follow-up; 1.2%, 95% CI, 0.6% to 2.5%), 6 regional recurrences (one combined with IBTR), 2 distant recurrences (both without IBTR or regional recurrence) and 13 contralateral breast cancers were observed. There were 48 deaths. One death (2.1%) was due to breast cancer and 13 (27.1%) were due to other cancers (2 endometrial cancers). Five-year overall survival was 93.0% (95% CI, 90.5% to 94.9%).

    Conclusion: BCS and ET without RT seem to be a safe treatment option in women >= 65 years with early breast cancer and favorable histopathology. The risk of IBTR is comparable to the risk of contralateral breast cancer. Moreover, concurrent morbidity dominates over breast cancer as leading cause of death in this cohort with low-risk breast tumors. (C) 2018 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

  • 13.
    Wickberg, Åsa
    et al.
    Örebro University, School of Medical Sciences. Department of Surgery.
    Magnuson, Anders
    School of Medical Sciences, Örebro University, Örebro, Sweden.
    Holmgren, Lars
    Uppsala University, Uppsala, Sweden; King’s College, London, United Kingdom.
    Adami, Hans-Olov
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Clinical Effectiveness Research Group, University of Oslo, Oslo, Norway.
    Liljegren, Göran
    Department of Surgery, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    Influence of the subtype on local recurrence risk with or without radiotherapy in a randomized trialManuscript (preprint) (Other academic)
  • 14.
    Wickberg, Åsa
    et al.
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Surgery.
    Prag, Clara
    Department of Surgery, Faculty of Medicine and Health, Örebro University, Örebro, Örebro, Sweden.
    Valachis, Antonis
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Oncology.
    Karlsson, Leif
    Department of medical Physics, Örebro University Hospital, Örebro, Sweden.
    Johansson, Bengt
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Oncology.
    Intraoperative Radiation Therapy Delivered by Brachytherapy in Breast Cancer: An Interim Analysis of a Phase 2 Trial2024In: Clinical Breast Cancer, ISSN 1526-8209, E-ISSN 1938-0666, Vol. 24, no 3, p. 243-252Article in journal (Refereed)
    Abstract [en]

    PURPOSE: Intraoperative breast cancer radiotherapy (IORT) offers an alternative to external beam radiotherapy (EBRT) after breast-conserving surgery (BCS). The Intraoperative brachytherapy (IOBT) trial applies high dose rate (HDR) brachytherapy with a new applicator prototype as IORT after BCS. In this interim analysis of the IOBT trial, we present the oncological safety and toxicity of the method.

    METHODS: Eligible patients were women, ≥ 50 years old with an unifocal nonlobular, estrogen-receptor-positive, HER2-negative breast cancer, cN0, ≤ 3 cm, treated with BCS and sentinel node biopsy (SNB). Toxicity was registered according to the LENT-SOMA scale. Cumulative incidence of local (LR) and regional recurrence (RR) were calculated through cumulative incidence function whereas overall survival (OS) was illustrated through Kaplan-Meier curve.

    RESULTS: Until February 2023, 155 women (median age 68 years) were included in the trial. Twenty-nine women (18.7%) received supplemental EBRT, mostly due to positive SNB. Three-year cumulative incidence of LR and RR were 1.0% (CI 95 % 0.1%-2.3%) and 2.1% (CI 95% 0.8%-4.2%) respectively. Five- year cumulative incidence of LR and RR were 3.9% (CI 95% 1.8%-6.4%) and 2.1% (CI 95% 0.8%-4.2%) respectively. Five-year OS was 96.3% (CI 95% 93.6%-98.4%). Side effects were limited, low grade, and transient.

    CONCLUSION: Acknowledging the short median follow-up time at interim analysis, our initial results indicate that delivering IORT through HDR brachytherapy in carefully selected breast cancer patients is feasible and oncological safe so far. A long-term follow-up is essential to confirm the initial results.

1 - 14 of 14
CiteExportLink to result list
Permanent link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf